Cargando…

Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disease with limited treatment options. Therefore, the identification of therapeutic targets is urgently needed. Previous studies have shown that the ligand activation of the sigma-1 chaperone (Sigma1R) promotes neuroprotection. The multita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voronin, Mikhail V., Kadnikov, Ilya A., Voronkov, Dmitry N., Seredenin, Sergey B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863824/ https://www.ncbi.nlm.nih.gov/pubmed/31745133 http://dx.doi.org/10.1038/s41598-019-53413-w

Ejemplares similares

Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson’s Disease
por: Kadnikov, Ilya A., et al.
Publicado: (2020)

Contribution of Sigma‐1 receptor to cytoprotective effect of afobazole
por: Voronin, Mikhail V., et al.
Publicado: (2016)

Chaperone Sigma1R and Antidepressant Effect
por: Voronin, Mikhail V., et al.
Publicado: (2020)

Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole
por: Voronin, Mikhail V., et al.
Publicado: (2021)

Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection
por: Voronin, Mikhail V., et al.
Publicado: (2023)

Neuroprotective Properties of Quinone Reductase 2 Inhibitor M-11, a 2-Mercaptobenzimidazole Derivative
por: Voronin, Mikhail V., et al.
Publicado: (2021)

Activation of Sigma Receptors With Afobazole Modulates Microglial, but Not Neuronal, Apoptotic Gene Expression in Response to Long-Term Ischemia Exposure
por: Behensky, Adam A., et al.
Publicado: (2019)

Pharmacological Analysis of GABA(A) Receptor and Sigma1R Chaperone Interaction: Research Report I―Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABA(A) Receptors’ Ligands
por: Voronin, Mikhail V., et al.
Publicado: (2023)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA
por: Tu, Li, et al.
Publicado: (2019)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Neuroprotective activity of Stereospermum suaveolens DC against 6-OHDA induced Parkinson's disease model
por: Shalavadi, M. H., et al.
Publicado: (2012)

Neuroprotective Effect of 1,4-Naphthoquinones in an In Vitro Model of Paraquat and 6-OHDA-Induced Neurotoxicity
por: Menchinskaya, Ekaterina, et al.
Publicado: (2021)

Astrocytic Expression of GSTA4 Is Associated to Dopaminergic Neuroprotection in a Rat 6-OHDA Model of Parkinson’s Disease
por: Jewett, Michael, et al.
Publicado: (2017)

The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease
por: Yu, Hao, et al.
Publicado: (2021)

Neuroprotective effects of kukoamine A on 6-OHDA-induced Parkinson's model through apoptosis and iron accumulation inhibition
por: Li, Xin, et al.
Publicado: (2020)

Agathobaculum butyriciproducens Shows Neuroprotective Effects in a 6-OHDA-Induced Mouse Model of Parkinson’s Disease
por: Lee, Da Woon, et al.
Publicado: (2022)

Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons
por: Ji Yuan, Wen, et al.
Publicado: (2008)

Analysis of Antidepressant-like Effects and Action Mechanisms of GSB-106, a Small Molecule, Affecting the TrkB Signaling
por: Vakhitova, Yulia V., et al.
Publicado: (2021)

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model
por: C. Gonçalves, Valeria, et al.
Publicado: (2020)

Neuroprotective Effect of Optimized Yinxieling Formula in 6-OHDA-Induced Chronic Model of Parkinson's Disease through the Inflammation Pathway
por: Wei, Renrong, et al.
Publicado: (2019)

Genomic Action of Sigma-1 Receptor Chaperone Relates to Neuropathic Pain
por: Wang, Shao-Ming, et al.
Publicado: (2021)

Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity
por: Huang, Chun, et al.
Publicado: (2018)

Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties
por: Ximenes, José Christian Machado, et al.
Publicado: (2015)

Galangin Exhibits Neuroprotective Effects in 6-OHDA-Induced Models of Parkinson’s Disease via the Nrf2/Keap1 Pathway
por: Chen, Qiu-Xu, et al.
Publicado: (2022)

Erratum to “Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effect of bFGF in the 6-OHDA-Induced Parkinson’s Disease Model”
por: Cai, Pingtao, et al.
Publicado: (2023)

Correction to: Genomic Action of Sigma-1 Receptor Chaperone Relates to Neuropathic Pain
por: Wang, Shao-Ming, et al.
Publicado: (2021)

Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity
por: Zhang, Ning, et al.
Publicado: (2014)

Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease
por: Neves, Kelly Rose Tavares, et al.
Publicado: (2015)

Neuroprotective Effect of Bergamot Juice in 6-OHDA-Induced SH-SY5Y Cell Death, an In Vitro Model of Parkinson’s Disease
por: Ferlazzo, Nadia, et al.
Publicado: (2020)

Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone
por: Rodrigues, Laís D., et al.
Publicado: (2019)

Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson’s Disease
por: Barata-Antunes, Sandra, et al.
Publicado: (2020)

Neuroprotective Properties of Bis-Sulfonamide Derivatives Against 6-OHDA-Induced Parkinson's Model via Sirtuin 1 Activity and in silico Pharmacokinetic Properties
por: Apiraksattayakul, Setthawut, et al.
Publicado: (2022)

Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson’s disease
por: Collins, Louise M, et al.
Publicado: (2014)

Palmitate and Stearate are Increased in the Plasma in a 6-OHDA Model of Parkinson’s Disease
por: Shah, Anuri, et al.
Publicado: (2019)

A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats
por: Choudhury, Mohammed Emamussalehin, et al.
Publicado: (2011)

Parkinson’s Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1
por: Tan, Jolene Su Yi, et al.
Publicado: (2022)

The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)
por: Yang, Kai, et al.
Publicado: (2019)

Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson’s disease
por: Chen, William Shao-Tsu, et al.
Publicado: (2023)

Glucose Homeostasis Is Not Affected in a Murine Model of Parkinson’s Disease Induced by 6-OHDA
por: Gomes, Felipe Azevedo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8h9u3emc7es8egkm952d4gvspt